Mitochondrial dynamics changes with age in an APPsw/PS1dE9 mouse model of Alzheimer’s disease
Lin-Lin Xu, Yang Shen, Xiao Wang, Li-Fei Wei, Ping Wang, Hui Yang, Cun-Fu Wang, Zhao-Hong Xie and Jian-Zhong Bi

Increasing research suggests that mitochondrial defects play a major role in Alzheimer’s disease (AD) pathogenesis. We aimed to better understand changes in mitochondria with the development and progression of AD. We compared APPsw/PS1dE9 transgenic mice at 3, 6, 9, and 12 months old as an animal model of AD and age-matched C57BL/6 mice as controls. The learning ability and spatial memory ability of APPsw/PS1dE9 mice showed significant differences compared with controls until 9 and 12 months. Mitochondrial morphology was altered in hippocampus tissue of APPsw/PS1dE9 mice beginning from the third month. ‘Medullary corpuscle’, which is formed by the accumulation of a large amount of degenerative and fragmented mitochondria in neuropils, may be the characteristic change observed on electron microscopy at a late stage of AD. Moreover, levels of mitochondrial fusion proteins (optic atrophy 1 and mitofusin 2) and fission proteins (dynamin-related protein 1 and fission 1) were altered in transgenic mice compared with controls with progression of AD. We found increased levels of fission and fusion proteins in APP/PS1 mice at 3 months, indicating that the presence of abnormal mitochondrial dynamics may be events in early AD progression. Changes in mitochondrial dynamics preceded the onset of memory decline as measured by the modified Morris water maze test. Abnormal mitochondrial dynamics could be a marker for early diagnosis of AD and monitoring disease progression. Further research is needed to study the signaling pathways that govern mitochondrial fission/fusion in AD. NeuroReport 2017, 28:222–228 Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc.

NeuroReport 2017, 28:222–228

Keywords: Alzheimer’s disease, mitochondrial dynamics, mitochondrial dysfunction, mitochondrial fission, mitochondrial fusion

*Department of Neurology, Second Hospital, †Institute of Neurology and ‡Key Laboratory of Translational Medicine on Neurological Degenerative Disease, Shandong University, Jinan, China

Correspondence to Jian-Zhong Bi, MD, Department of Neurology, Second Hospital, Shandong University, Jinan 250033, Shandong, China

Tel: +86 531 85875006; fax: +86 531 88962544;
e-mail: bjz@sdu.edu.cn

Received 14 December 2016 accepted 5 January 2017

Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by progressive memory loss, behavioral language, visuospatial impairments, and changes in personality [1]. AD is characterized by loss of neurons, intracellular neurofibrillary tangles, and extracellular senile plaques composed of β-amyloid deposits [2]. However, increasing research suggests that mitochondrial defects play a major role in the pathogenesis of AD [3–5]. Mitochondria are the powerhouses of all cells except erythrocytes. Neurons are especially vulnerable to mitochondrial dysfunction owing to high energy demands and dependence on respiration for ATP generation [6]. Multiple studies have found reduced levels of mitochondrial ATP in affected brain regions of AD transgenic mice [7,8], which further suggests that mitochondrial dysfunction is a significant characteristic of AD pathogenesis. Mitochondrial defects might arise from abnormal mitochondrial dynamics [9].

Mitochondria are highly dynamic and plastic organelles that are continually altering morphology by rapid and reversible fission and fusion [10]. Fission is regulated by dynamin-related protein 1 (DRP1, GTPase) and fission 1 (FIS1), and fusion is regulated by optic atrophy 1 (OPA1) responsible for inner-membrane fusion; mitofusins (MFN1 and MFN2) are responsible for outer-membrane fusion [11,12]. Mitochondrial dynamics are essential for cell survival. However, neurons affected by AD feature unbalanced mitochondrial dynamics, which results in structural and functional abnormalities, leading to neuronal damage [5].

Abnormal mitochondrial dynamics in the pathogenesis of AD is becoming a research hotspot [13]. Multiple studies report mitochondrial dysfunction selectively in cortical and hippocampal postmortem brain tissues from AD patients [14] and AD transgenic mice [15]. More recently, a study found reduced levels of DRP1, OPA1, MFN1, and MFN2 and increased levels of FIS1 in brain tissue from AD patients [16]. Impaired mitochondrial dynamics (increased mitochondrial fission and decreased fusion) may explain the increased mitochondrial fragmentation, defective mitochondrial function, impaired axonal transport of mitochondria, and synaptic
degeneration observed in neurons affected by AD [17].
Increasing evidence suggests structural and functional
abnormalities in mitochondria involved in AD [15,16].
However, in AD neurons, the extent and characteristics of
mitochondrial structural damage and mitochondrial proteins at
different stages of the disease are still unclear.

Materials and methods
Animals and tissues
Heterozygous β-amyloid PSwε/PS1dE9 double-transgenic
mice (APP/PS1) with a C57BL/6 background and age-
matched C57BL/6 control mice (C57) at age 3, 6, 9, and
12 months were used. All mice were males (n = 15 per
group) and all were obtained from Beijing HFK Bioscience,
Beijing, China (Permit no. scxk 2014-0004). Mice were
depth euthanized by 10% chloral hydrate, followed by
cervical dislocation. Within 3 min, the brains were rapidly
removed; one hemisphere was dissected for electron
microscopy and the other was used for Western blotting. All
procedures followed the guidelines of the Ethical
Committee for Animal Experiments of Shandong
University (Jinan, China).

Behavior test
We used the modified Morris water maze test to assess
learning and spatial memory ability of mice [18]. The
procedure consisted of 1-day adapting tests without a
platform and 5-day hidden platform tests, plus a spatial
probe trial 24 h after the last hidden platform test; 15
mice were used in each group. In the spatial acquisition
tests, the longest time in finding the platform was 60 s. If
a mouse did not find the platform within 60 s, it was
guided to the platform. Every mouse was trained four
times per day. The platform was located in the southwest
quadrant of the water tank. Starting locations were
semirandomly selected at the north, east, southeast, and
northwest corners. The time taken for a mouse to explore
and arrive at the platform was recorded as the escape
latency. After 24 h of the last hidden platform test had
been completed, a single probe trial was performed to
test memory retention, in which the platform was
removed. The new start location was northeast and each
mouse was allowed to swim for 60 s. The time spent
traveling in the target quadrant (where the platform was
previously located) was recorded and the times crossing
the point where the platform had been located were
counted to test whether they remembered the original
position of the platform.

Transmission electron microscopy
According to the conventional transmission electron
microscopy (TEM) sample preparation method [19], dis-
sected hippocampus CA1 was quickly cut into 1-mm-thick
slices and immediately placed in 3% glutaraldehyde in
phosphate buffer for 2 h. The slices were then postfixed in
a 1% osmium-tetroxide PBS for 1 h, and subsequently
rinsed, dehydrated, saturated, and embedded in EPON812
resin. Then, ultrathin slices were cut on an ultramicrotome
after semithin sections positioning. They were then rinsed
and poststained with lead citrate and uranyl acetate and
imaged under a JEM-1200 EX electron microscope (JEOL
Ltd., Tokyo, Japan). Overall, 15–20 randomly selected
micrographs per group were obtained at 15,000 magnifica-
tion and analyzed by a blinded investigator. Images of
mitochondria in cell bodies of 15 CA1 neurons were
obtained. Mitochondrial length in neurons was measured
using Image J software (NIH Image for the Macintosh,
Cupertino, California, USA).

Western blot analysis
For Western blot, hippocampus tissues were flash frozen
and then stored at −80°C until homogenization. Tissues
were homogenized for 30 min in ice-cold RIPA lysing
buffer [25 mM Tris–HCl (pH 7.6), 150 mM NaCl; 1% NP40;
1% sodium deoxycholate; 0.1% sodium deox-
ycholate, 0.1% SDS] for a radioimmunoprecipitation
assay (Redwood City, California, USA). Protein levels
were tested using the bicinchoninic acid method. We
prepared a 10% separation gel and a 5% stacking gel.
Proteins were separated by SDS-PAGE (140 V), then
transferred to a polyvinylidene fluoride membrane
(150 mA, constant current, 2 h) and incubated for 1 h at
room temperature with 5% skim milk in tris-buffered
saline/t solution and then with primary antibodies over-
night at 4°C. The membranes were washed with a tris-
buffered saline/t buffer three times (5 min/time) and then
incubated for 1 h with secondary antibodies. Proteins
were exposed by electrochemiluminescence; membranes
were washed three times at 5 min intervals and analyzed
using a PharosFX Plus Molecular Imager (Bio-Rad). The
antibodies were anti-DRP1 (8570, 1 : 1000; Cell Signaling
Technology, Danvers, Massachusetts, USA), anti-FIS1
(10956-1-Ap, 1 : 500; Proteintech), anti-MFN2 (ab124773, 1:1000; Abcam, Cambridge, Massa-
chusetts, USA), anti-OPA1 (ab157457, 1 : 1000; Abcam), and
anti-β-actin (20536-1-Ap, 1 : 2000; Proteintech).

Statistical analysis
All data are expressed as mean ± SD and were analyzed
using SPSS 17.0 (SPSS Inc., Chicago, Illinois, USA). The
water maze data were analyzed by analysis of variance and
with multiple variables by multifactor analysis of variance.
Multiple comparisons between means involved the least
significant difference or the Student–Newman–Keuls
method. Significance was set at P less than 0.05.

Results
Spatial learning and memory impairments in APP/PS1
mice
Spatial learning was measured as escape latency in the
water maze each day (n = 15 mice in each group). Over
the 5 days of training, the escape latency of each group
reduced gradually (Fig. 1b–e). The escape latency of
APP/PS1 mice was longer than controls, and showed
Spatial learning and memory impairments in APP/PS1 Mice. Escape latency, number of platform location crossings, and time spent in the target quadrant for transgenic and control C57 mice at age 3, 6, 9, and 12 months. (a) The escape latency of APP/PS1 mice was longer than the controls, and showed significant differences until 9 ($P=0.047$) and 12 months ($P=0.021$) compared with C57 mice. (b–e) Over the 5 days of training, the escape latency of each group reduced gradually. (b) Data from 3-month-old mice. (c) Data from 6-month-old mice. (d) Data from 9-month-old mice ($P=0.048$). (e) Data from 12-month-old mice ($P=0.042$). (f) Number of platform location crossings ($P=0.046$). (g) Time spent in the target quadrant. Data are presented as mean ± SE, $^*P<0.05$, $n=15$ in each group.
significant differences until 9 and 12 months compared with C57 mice. However, no statistical differences were detected at 3 and 6 months (Fig. 1a).

Spatial memory was evaluated by the probe trial performed 24 h after the last training session. The number of platform location crossings and the time spent in the target quadrant of APP/PS1 mice were consistently lower and shorter than those of the controls, which suggests an overall significance. However, the times crossing platform location of APP/PS1 mice at 12 months compared with C57 mice show only a significant difference out of eight comparisons (Fig. 1f and g).

Thus, the learning ability and spatial memory ability of APP/PS1 transgenic mice showed significant differences compared with age-matched C57 mice until 9 and 12 months.

**Altered mitochondrial morphology in APP/PS1 mice precedes the onset of memory deficit**

TEM was used to observe the hippocampus CA1 zone ultrastructure of APP/PS1 transgenic and C57 mice at different ages. Mitochondrial morphology changes in APP/PS1 mice started at age 3 months compared with the length and shape of mitochondria in C57 brains at the same age (Fig. 2). Several elongated mitochondria were identified, mitochondria gathered around the nucleus, and mitochondria were increased in number because of the increased formation of the mitochondrial split ring (Table 1). A mitochondrion divides by developing a ring around the organelle that constricts to pinch it into two halves. However, mitochondrial split rings were rare and mitochondria were larger (Fig. 2 and Table 1). Many fragmented mitochondria marked with disrupted membranes and without clear cristae appeared in APP/PS1 transgenic mice at the age of 6 months (Fig. 2 and Table 1). Then, the number of mitochondria split rings increased significantly for many damaged degenerative and fragmented mitochondria in AD mouse brains at the age of 9 months (Fig. 2). Finally, the ‘medullary corpuscle’ (an accumulation of small mitochondria and structurally damaged mitochondria with broken cristae) was found in neuropils in APP/PS1 transgenic mice at the age of 12 months (Fig. 2). These mitochondria changes were rarely observed in C57 mouse tissues (Fig. 2 and Table 1). Therefore, the changes in mitochondrial morphology started at age 3 months in APP/PS1 mouse models before the onset of memory decline.

**Discussion**

In this study, we show that mitochondrial dynamics changes differ in APP/PS1 mice with age compared with controls and that mitochondrial morphology changes occur in APP/PS1 mice before the onset of memory decline. We used the modified Morris water maze test and showed that the spatial learning and memory of APP/PS1 mice was significantly decreased compared with controls until 9 and 12 months.

By TEM, we found mitochondrial fragmentation in neurons in all stages of the AD mouse brain, which is consistent with the altered ultrastructure observed in AD neurons from human brains and other mouse models [20,21]. Mitochondrial fragmentation increased with disease progression, but before the onset of the memory phenotype. The ‘medullary corpuscle’, which is formed by the accumulation of a large amount of degenerative and fragmented mitochondria in neuropils, may be the characteristic change at the late stage of AD.

Changes in mitochondrial morphology may affect mitochondrial function [22]. However, mitochondrial morphology is regulated by the balance of mitochondrial fission and fusion [23]. Mitochondrial dynamics control the shape, localization, and function of mitochondria [24]. How mitochondrial dynamics alter during AD development and progression remains unclear. A clearer understanding may provide new therapies for AD.

We studied mitochondrial structural proteins with disease progression and found differences in the expression of mitochondrial fusion and fission proteins in APP/PS1 mice compared with age-matched C57 mice with aging. In 3-month-old APP/PS1 mice, fission proteins (DRP1 and FIS1) and fusion proteins (OPA1 and MFN2) were significantly increased in APP/PS1 mice at the age of 3 months compared with C57 mice (Fig. 3b–e). In contrast, levels of fission proteins DRP1 and FIS1 and mitochondrial inner-membrane fusion protein OPA1 were decreased at 6 months, but those of the mitochondrial outer-membrane fusion protein MFN2 were increased in APP/PS1 mice compared with C57 mice (Fig. 3b–e). Protein levels of DRP1, FIS1, OPA1, and MFN2 at 9 and 12 months were significantly increased compared with the controls (but not FIS1 at 9 months) (Fig. 3b–e). Our data suggest that the expression of fission and fusion proteins is altered in APP/PS1 mice with age and changes in mitochondrial morphology in APP/PS1 mice (Fig. 2) may be caused by altered expression of key proteins involved in mitochondrial dynamics.

**Altered expression of mitochondrial fission or fusion proteins may lead to changes in mitochondrial morphology**

To determine whether mitochondrial structural proteins are altered in levels as AD progresses, we compared the protein levels of DRP1, FIS1, MFN2, and OPA1 in hippocampus tissues from APP/PS1 and C57 mice at ages 3, 6, 9, and 12 months (Fig. 3a). Levels of proteins related to fission (DRP1 and FIS1) and fusion (OPA1 and MFN2) were significantly increased in APP/PS1 mice at the age of 3 months compared with C57 mice (Fig. 3b–e). In contrast, levels of fission proteins DRP1 and FIS1 and mitochondrial inner-membrane fusion protein OPA1 were decreased at 6 months, but those of the mitochondrial outer-membrane fusion protein MFN2 were increased in APP/PS1 mice compared with C57 mice (Fig. 3b–e).
Mitochondrial morphology is altered in the hippocampus of APP/PS1 mice. (a) Hippocampus CA1 zone ultrastructure of C57 mice at age 3, 6, 9, and 12 months. (b) Hippocampus CA1 zone ultrastructure of APP/PS1 mice at age 3, 6, 9, and 12 months. (c) Each one of the images is the enlarged version of the correspondingly arrowheaded area above in (b). Arrows show altered mitochondria: (M3) elongated mitochondria with mitochondrial split rings formed. (M6) fragmented mitochondria marked with disrupted membranes and without clear cristae. (M9) mitochondria split rings increased significantly. (M12) ‘medullary corpuscle’ formed by the accumulation of a large amount of degenerative and fragmented mitochondria in neuropils. These mitochondria changes were rarely observed in C57 mouse tissues. M, months.

Table 1  Quantitative analysis of mitochondria in CA1 neuronal cell bodies from APPsw/PS1dE9 and C57 mice on the basis of an electron microscopy examination

| Genotypes   | Age (months) | Total number of mitochondria | Number of abnormal mitochondria | Average mitochondrial length (μm) |
|-------------|-------------|-----------------------------|---------------------------------|----------------------------------|
|             |             |                            | Elongated | Fragmented | Split ring | ‘Medullary corpuscle’ | Formed |                                      |
| APPsw/PS1dE9 | 3           | 307                         | 38        | 18         | 29         | 0                    | 0.52 ± 0.46* |
|             | 6           | 299                         | 19        | 41         | 6          | 0                    | 0.60 ± 0.41* |
|             | 9           | 382                         | 14        | 45         | 86         | 0                    | 0.58 ± 0.26 |
|             | 12          | 390                         | 24        | 72         | 57         | 21                   | 0.44 ± 0.17  |
| C57         | 3           | 227                         | 10        | 13         | 5          | 0                    | 0.37 ± 0.08  |
|             | 6           | 183                         | 9         | 17         | 4          | 0                    | 0.38 ± 0.18  |
|             | 9           | 267                         | 12        | 19         | 25         | 0                    | 0.59 ± 0.36  |
|             | 12          | 355                         | 16        | 23         | 23         | 0                    | 0.39 ± 0.15  |

*P<0.05 versus age-matched C57 mice.

progressively in APP/PS1 mice at 9 and 12 months compared with the controls (but not FIS1 at 9 months).

Overall, our data suggest that changes in mitochondrial structural proteins in APP/PS1 and C57 mice correlate with genotype and age. We found increased levels of fission and fusion proteins in APP/PS1 mice at 3 months, indicating that the presence of abnormal mitochondrial dynamics may be events in early AD progression. Wang and colleagues found that APP overexpression reduced the levels of DLP1 and OPA1, which is in agreement with our observation of APP/PS1 mice at 6 months. However, what stage of AD
progression was studied in APP-overexpressing M17 cells in the study by Wang and colleagues is unclear. Wang et al. [25] also reported that the manipulation of OPA1 but not DRP1 or FIS1 level rescued mitochondrial fragmentation. In contrast to the study by Wang and colleagues, Manczak et al. [9] reported that DRP1 and FIS1 levels increased significantly and progressively in patients with early, definite, and severe AD, but levels of MFN1 and MFN2 fusion proteins decreased. Some of the Manczak and colleagues findings are in agreement with those in our study because we found that DRP1 and FIS1 levels increased in APP/PS1 mice at 3, 9, and 12 months. However, in our study, the level of MFN2 fusion protein was increased. The differences in results may be because of the choice of control group and the aim of the study.

Conclusion
The above findings led to the conclusion that mitochondrial morphology and mitochondrial dynamics in AD pathogenesis are age related, which are significant in
developing new treatment strategies by modifying abnormal mitochondrial dynamics in AD at different stages of disease progression. More importantly, we found that the progressive decline of memory appears later than mitochondrial dysfunction in APP/PS1 transgenic mice with disease progression; thus, abnormal mitochondrial dynamics may be early events in AD progression. These changes may provide us with new insight to study the mechanism of AD and could be used for early diagnosis and monitoring of AD progression. However, appropriate manipulation of fission and fusion genes to ameliorate neurodegenerative processes will be a challenge because the requirements for fission and fusion differ between cell types and cellular compartments.

Acknowledgements
This research was supported by the Youth Foundation of the 2nd Hospital of Shandong University (Y2014010010) and the National Natural Science Foundation of China (Nos. 81171214, 81571052, and 81401052) and Key projects of Research and development of Shandong province (2015GSF118056).

Conflicts of interest
There are no conflicts of interest.

References
1 Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet 2011; 377:1019–1031.
2 Anandatheerthavarada HK, Devi L. Amyloid precursor protein and mitochondrial dysfunction in Alzheimer’s disease. Neuroscientist 2007; 13:626–638.
3 Swerdlow RH. The neurodegenerative mitochondriopathies. J Alzheimers Dis 2009; 17:737–751.
4 Martin LJ. Mitochondrial and cell death mechanisms in neurodegenerative diseases. Pharmaceuticals (Basel) 2010; 3:839–915.
5 Reddy PH, Reddy TP. Mitochondria as a therapeutic target for aging and neurodegenerative diseases. Curr Alzheimer Res 2011; 8:393–409.
6 Du H, Guo L, Yan SS. Synaptic mitochondrial pathology in Alzheimer’s disease. Antioxid Redox Signal 2012; 16:1467–1475.
7 Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in female mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 2009; 106:14670–14675.
8 Dragicevic N, Manczak M, Zhu Y, Buzzeo R, Tan J, Arendash GW, Bradshaw PC. Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer’s transgenic mice. J Alzheimers Dis 2010; 20 (Suppl 2):S535–S550.
9 Manczak M, Calkins MJ, Reddy PH. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: implications for neuronal damage. Hum Mol Genet 2011; 20:2495–2509.
10 Okamoto K, Shaw JM. Mitochondrial morphology and dynamics in yeast and multicellular eukaryotes. Annu Rev Genet 2005; 39:503–536.
11 Hall AR, Burke N, Dongworth RK, Hausenloy DJ. Mitochondrial fusion and fission proteins: novel therapeutic targets for combating cardiovascular disease. Br J Pharmacol 2014; 171:1890–1906.
12 Cho DH, Nakamura T, Lipton SA. Mitochondrial dynamics in cell death and neurodegeneration. Cell Mol Life Sci 2010; 67:3435–3447.
13 Santos RX, Correia SC, Wang X, Perry G, Smith MA, Moreira PI, Zhu X. Alzheimer’s disease: diverse aspects of mitochondrial malfunctioning. Int J Clin Exp Pathol 2010; 3:570–581.
14 Devi L, Prabhu BM, Galati DF, Avadhani NG, Anandatheerthavarada HK. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer’s disease brain is associated with mitochondrial dysfunction. J Neurosci 2006; 26:9057–9068.
15 Manczak M, Mao P, Calkins MJ, Correia A, Reddy AP, Murphy MP, et al. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer’s disease neurons. J Alzheimers Dis 2010; 20 (Suppl 2):S609–S631.
16 Wang X, Su B, Lee HG, Li X, Perry G, Smith MA, Zhu X. Impaired balance of mitochondrial fission and fusion in Alzheimer’s disease. J Neurosci 2009; 29:9090–9103.
17 Calkins MJ, Manczak M, Mao P, Shirendeb U, Reddy PH. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer’s disease. Hum Mol Genet 2011; 20:4515–4529.
18 Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc: 2006; 1:848–858.
19 Yan J, Liu XH, Han MZ, Wang YM, Sun XL, Yu N, et al. Blockage of GSK3beta-mediated Drp1 phosphorylation provides neuroprotection in neuronal and mouse models of Alzheimer’s disease. Neurobiol Aging 2015; 36:211–227.
20 Yu T, Jhun BS, Yoon Y. High-glucose stimulation increases reactive oxygen species production through the calcium and mitogen-activated protein kinase-mediated activation of mitochondrial fission. Antioxid Redox Signal 2011; 14:425–437.
21 Du H, Yan SS. Mitochondrial medicine for neurodegenerative diseases. Int J Biochem Cell Biol, 42:560–572.
22 Chen H, Chomy A, Chan DC. Disruption of fusion results in mitochondrial heterogeneity and dysfunction. J Biol Chem 2006; 280:26185–26192.
23 Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. Cell 2008; 135:1241–1252.
24 Santos RX, Correia SC, Wang X, Perry G, Smith MA, Moreira PI, Zhu X. A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer’s disease. J Alzheimers Dis 2010; 20 (Suppl 2):S401–S412.
25 Wang X, Su B, Siedlak SL, Moreira PI, Fujikawa H, Wang Y, et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci USA 2008; 105:19318–19323.